Last updated on January 2020

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Toxic Shock Syndrome
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

All the following criteria must be fulfilled:

  1. Adult intensive care patients (age 18 years)
  2. Septic shock defined according to the Sepsis-3 criteria:
    • suspected or documented infection
    • persisting hypotension requiring vasopressors to maintain a mean arterial blood pressure of 65 mmHg or above
    • Lactate level of 2 mmol/L or above despite fluid therapy within the last 3 hours at screening
  3. Soluble thrombomodulin (sTM) above 10 ng/mL

Exclusion Criteria:

Patients who fulfil any of the following criteria will be excluded:

  1. Withdrawal from active therapy
  2. Pregnancy
  3. Known hypersensitivity to iloprost.
  4. Life-threatening bleeding as defined by the treating physician
  5. Known severe heart failure (New York Heart Association (NYHA) class IV)
  6. Suspected acute coronary syndrome
  7. Previously included in this trial
  8. Septic shock for more than 12 hours at the time of screening
  9. Informed consent cannot be obtained
  10. Included in other clinical trials with prostacyclin within 90 days

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.